Antibody Shows Positive Results in Hep C Trial
REHOVOT, Israel-Officials from XTL Biopharmaceuticals are reporting positive results of the first monoclonal antibody to treat hepatitis C (HCV).
XTL-002, the company's monoclonal antibody, has been tested in Phase 1a studies and has reportedly reduced HCV and RNA levels in more than half the patients treated with one dose.
There were no serious adverse effects reported of the intravenous infusions. XTL-002 is a human high-affinity monoclonal antibody.
Hepatitis C is a viral bloodborne disease that attacks the liver and can cause jaundice, fatigue, pain, and vomiting. It can lead to liver damage and cancer. There are an estimated 4 million Americans who have the virus.
XLT Biopharmaceuticals is working on a group of therapies designed to fight a variety of chronic viral infections, drug-resistant bacteria, and systemic fungal infections.
Beyond the Surface: Rethinking Environmental Hygiene Validation at Exchange25
June 30th 2025Environmental hygiene is about more than just shiny surfaces. At Exchange25, infection prevention experts urged the field to look deeper, rethink blame, and validate cleaning efforts across the entire care environment, not just EVS tasks.
A Controversial Reboot: New Vaccine Panel Faces Scrutiny, Support, and Sharp Divides
June 26th 2025As the newly appointed Advisory Committee on Immunization Practices (ACIP) met for the first time under sweeping changes by HHS Secretary Robert F. Kennedy Jr, the national spotlight turned to the panel’s legitimacy, vaccine guidance, and whether science or ideology would steer public health policy in a polarized era.
Getting Down and Dirty With PPE: Presentations at HSPA by Jill Holdsworth and Katie Belski
June 26th 2025In the heart of the hospital, decontamination technicians tackle one of health care’s dirtiest—and most vital—jobs. At HSPA 2025, 6 packed workshops led by experts Jill Holdsworth and Katie Belski spotlighted the crucial, often-overlooked art of PPE removal. The message was clear: proper doffing saves lives, starting with your own.
